Fig. 4

Chloroquine potentiates the antitumor effect of ipatasertib and taselisib in TNBC cells a-d The addition of CQ 1-10 µM to ipatasertib and taselisib inhibits cell proliferation in MDAMB231 and MDAMB468 cell lines, measured by SRB assay after 72 h and expressed as % of CTL. Each experiment is representative of three independent experiments. b By citofluorimetric assay, CQ 10 µM in combination with taselisib 10 µM, increases apoptosis, as measured by enhancement of Annexin V-FITC and Propidium Iodide, after 24 of treatment in MDAMB231, expressed as % of CTL e CQ alone or in combination with ipatasertib 1 µM, increases apoptosis, as measured by enhancement of Annexin V-FITC and Propidium Iodide, after 48 h of treatment in MDAMB468, expressed as % of CTL. Each experiment is representative of three independent experiments. c Daily exposure for 10 days of low dose (58 nM) of CQ reduces clonogenic proliferation of MDAMB231 cell line alone or in combination with ipatasertib and taselisib (1 µM). Cell growth was represented as % of CTL. f Daily exposure for 10 days of low dose (1 µM) of CQ reduces clonogenic proliferation of MDAMB468 cell line in combination with ipatasertib and taselisib (1 µM). Cell growth was represented as % of CTL. Each experiment is representative of three independent experiments. Statistically significant results are reported (*** indicates P < 0.0005, ** indicates P < 0.005 and * indicates P < 0.05)